Protagenic Therapeutics, Inc.\new: 10-Q filed 2019-11-14
What Protagenic Therapeutics, Inc.\new reported in its quarterly report filed 2019-11-14 (fiscal Q3 2019): 22 published measures, 70 facts as tagged in accession 0001493152-19-017362.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-11-14
- Fiscal period
- fiscal Q3 2019
- Accession
- 0001493152-19-017362 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Protagenic Therapeutics, Inc.\new filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 287,291 | USD | |
| At 2018-12-31 | 696,884 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -363,736 | USD | |
| At 2019-06-30 | -379,475 | USD | |
| At 2019-03-31 | -361,820 | USD | |
| At 2018-12-31 | -210,883 | USD | |
| At 2018-09-30 | 323,033 | USD | |
| At 2018-06-30 | 559,880 | USD | |
| At 2018-03-31 | 964,898 | USD | |
| At 2017-12-31 | 1,219,312 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 277,386 | USD | |
| At 2018-12-31 | 362,486 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -123,307 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -1,001,045 | USD | 273 |
| 2019-04-01 to 2019-06-30 | -278,506 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -599,232 | USD | 90 |
| 2018-07-01 to 2018-09-30 | -497,500 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -1,767,869 | USD | 273 |
| 2018-04-01 to 2018-06-30 | -672,210 | USD | 91 |
| 2018-01-01 to 2018-03-31 | -598,159 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | -338,570 | USD | 273 |
| 2018-01-01 to 2018-09-30 | -763,396 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 250,000 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 800,161 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -14,400,335 | USD | |
| At 2018-12-31 | -13,399,290 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 374 | USD | |
| At 2018-12-31 | 611 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 850,767 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 868,933 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -189,622 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -1,348,901 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -498,070 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -1,789,879 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 286,917 | USD | |
| At 2018-12-31 | 696,273 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 651,027 | USD | |
| At 2018-12-31 | 907,767 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 189,622 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 1,348,901 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 498,070 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 1,789,879 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 31,153 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 291,828 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 163,071 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 687,347 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 10,261,419 | shares | |
| At 2018-12-31 | 10,261,419 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 14,208,687 | USD | |
| At 2018-12-31 | 13,357,920 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -173,115 | USD | |
| At 2018-12-31 | -170,540 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -123,307 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -1,001,045 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -497,500 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -1,767,869 | USD | 273 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -123,327 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -1,008,443 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -497,985 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -1,765,212 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 158,469 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 1,057,073 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 334,999 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 1,102,532 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 254 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 262 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 66,315 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 347,856 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 570 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 22,010 | USD | 273 |
Inspect the source
- Entity
- Protagenic Therapeutics, Inc.\new / CIK 0001022899
- Captured
- 2026-09-20T05:13:45.961Z
- SEC response SHA-256
65b45c5addd26cd3e105dbeb1582537b1352dc73c447a8d926c77d81587fc033
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001022899.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))